Effect of multiprobiotic “Symbiter® acidophilic” concentrated on morphofunctional changes in stomach evoked by 28-days introduction of omeprazole
More details
Hide details
Department of Pharmaco-Physiology, Taras Shevchenko National University, Kiev, Ukraine
Olena Tsyryuk   

Kioto str., building 3, apt. 123, Kiev, 02156, Ukraine.
J Pre Clin Clin Res. 2010;4(1):52–56
Experiments on rats showed that 28-day injection of the antisecretory preparation omeprazole (14 mg/kg) resulted in a statistically significant increase in the gastrin level in blood plasma, which was accompanied by a significant inbalance between indices of stomach contamination by obligate and facultative microflora, by imbalanced stomach secretory function as well as by essential morphological changes in stomach. Multiprobiotic “Symbiter® acidophilic concentrated” introduced simultaneously with omeprazole during 28 days prevented the formation of disbiotic and partially morphological and functional changes in stomach. It was concluded that multiprobiotic “Symbiter® acidophilic concentrated” use was advisable in patients with hypergastrinemia of different genesis (hypoacidity/ anacidity, atrophic gastritis, long-term use of antisecretory drugs) and it can also be included in complex therapy of acid dependent diseases of the gastrointestinal tract to prevent development of disbacteriosis in the stomach, and as a result, to prevent morphological and functional changes in the stomach.
Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000, 406(6797), 782-787.
Borruel N, Carol M, Casellas F: Increased mucosal TNE production in Crohn’s disease can be downregulated ex vive by probiotic bacteria. Gut 2002, 51, 659-664.
Fossmark R, Johnsen G, Johanessen E, Waldum HL: Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005, 21(2), 149-154.
Ghosh MN, Shild HO: Continuous recording of acid gastric secretion in the rat. Br J Pharmacol Chemother 1958, 13(1), 54-61 .
Haller D, Bode C, Hammes WP: Non-pathogenic bacteria elicit a diff erential cytokine response by intestinal epithelial cell/leukocyte co-cultures. Gut 2000, 47, 79-87.
Hasselgren G, Hedenstrom H: Eff ect of esomeprazolee 40 mg vs omeprazolee 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal refl ux disease. Dig Dis Sci 2002, 47, 954-958.
Hirschowitz BI: Clinical aspects of ECL-cell abnormalities. Yale J Biol Med 1998, 71(3-4), 303-310.
Jalving M, Koornstra J, Wesseling J: Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006, 24(9), 1341-1348.
Jensen RT: Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006, 98(1), 4-19.
Laheij RJ, Sturkenboom MC, Hassing RJ: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292(16), 1955-1960.
Laine L, Fennerty M, Osato M: Esomeprazolee-based and the eff ect of antibiotic resistance: results of three US multicentre, double-blind trials Amer J Gastroenterol 2000, 95(12), 3393-3398.
Lilli P: Pathohistological technique and practical histochemistry. Mir, Moskow 1969, 648.
Martinsen TC, Taylor DM, Johnsen R: Gastric acidity protects mice against prion infection? Scand J Gastroenterol 2002, 37(5),497-500.
Mercenier A, Pavan S, Pot B: Probiotics as biotherapeutic agents: present knowledge ad future prospects. Curr Pharm Des 2003, 9, 175-191.
Miettinen M, Lehtonen A, Julkunen I: Lactobacilli and streptococci activate NF-kappa B and STAT signaling path ways in human macrophages. J Immunol 2000, 164, 3733-3740.
Naylor G., Axon A.: The role of bacterial overgrowth in the stomach as additional risk factor for gastritis. In: Helicobacter pylori. Basic mechanisms to Clinical Cure. Hunt RH (Ed.), Tytgat G.N.J, Dordrecht,Boston, London. Kluwer Academic Publishers 2002, 185- 194.
Nwokolo CU, Loft DE, Holder R, Langman MJS: Increased incidence of bacterial diarrhoea in patients taking gastric acid antisecretory drugs Eur J gastroenterol Hepatol 1994, 6, 697-699.
Oozeer R, Goupill-Feuillerat N, Alpert CA: Lactobacillus casei is able to survive and initiate protein synthesis during its transit in the digestive tract of human fl ora associated mice. Appl Eviron Micfobiol 2002, 68, 3570-3574.
Shanahan F: Probiotics and infl ammatory bowel disease: is there a scientifi c rationale? Infl amm Bowel Dis 2000, 6(2), 107-115.
Shao L, Serrano D, Mayer L: The role of epithelial cells in immune regulation in the gut. Semin Immunol 2001, 13, 163-175.
Socia E, Capella C, Flocca R, Rindi G, Rosai J: Gastric argyrophil cancinoidosis in patients with Zollinger Ellison syndrome due to type I multiple endocrine neoplasia: A newly recognized association Am J Surg Pathol 1990, 14, 503-513.
Waldum HL, Brenna E, Sandvik AK: Long-term safety of proton inhibitors: risk of gastric neoplasia and infections. Expert Opion Drug Saf 2002, 1, 29-38.
Watson SA, Grabowska AM, El-Zaatari M: Gastrin - active participant or bystander in gastric carcinogenesis? Nat Rev Cancer 2006, 6(12), 936-946.
Wilder-Smith CH, Spirig C, Krech T, Merki HS: Bactericidal factors in gastric juice. Eur J Gastroenterol Hepatol 1992, 4, 885-891.